Which of the following has the highest risk for EPS?

A. Clozapine (Clozaril) is a second-generation (atypical) antipsychotic with a high risk of weight gain, metabolic syndrome, and sedation due to its strong antagonism of histamine (H1) and serotonin (5-HT2C) receptors. It can also cause sexual dysfunction due to its impact on dopamine and prolactin levels.

B. Olanzapine (Zyprexa) has a significant risk of weight gain and metabolic side effects, similar to clozapine. It is known to cause hyperlipidemia, insulin resistance, and increased appetite, contributing to obesity. Sexual dysfunction can occur but is less common than with prolactin-elevating antipsychotics.

C. Haloperidol (Haldol) is a first-generation (typical) antipsychotic with a high risk of sexual dysfunction due to prolactin elevation from strong dopamine (D2) receptor blockade. While it has a lower risk of weight gain than atypical antipsychotics, it carries a high risk of extrapyramidal symptoms (EPS).

D. Aripiprazole (Abilify) is a partial dopamine agonist and has the lowest risk of weight gain among atypical antipsychotics. It also has a minimal impact on prolactin levels, reducing the risk of sexual dysfunction. Due to its unique mechanism, it is often preferred for patients concerned about metabolic side effects and sexual health.

A. Mesolimbic pathway is responsible for reward, motivation, and emotion. In schizophrenia, hyperactivity of this pathway leads to positive symptoms such as hallucinations, delusions, and disorganized thinking.

B. Nigrostriatal pathway regulates motor control. Dopamine blockade in this pathway leads to extrapyramidal symptoms (EPS) such as tremors, rigidity, and tardive dyskinesia, which are side effects of first-generation antipsychotics (typical antipsychotics).

C. Tuberoinfundibular pathway controls prolactin secretion. Dopamine inhibits prolactin release, so blocking D2 receptors with antipsychotics leads to hyperprolactinemia, causing gynecomastia, galactorrhea, and menstrual irregularities.

D. Mesocortical pathway is responsible for cognition, motivation, and emotional regulation. In schizophrenia, hypoactivity of this pathway is linked to negative symptoms such as apathy, anhedonia, social withdrawal, and cognitive impairment. Antipsychotics that block dopamine further worsen these symptoms, making negative symptoms more difficult to treat.